ALMKT:EPA
Mauna Kea Technologies SA
€0.097
arrow_upward
+0.62%(+0.00060) 1D
Oct 30, 5:35:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
18.26M
Avg. vol.
472.04K
Volume
291.17K
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.10
High
€0.10
Low
€0.09
Mkt. cap
18.26M
Avg. vol.
472.04K
Volume
291.17K
P/E ratio
0.83
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
ChartMill
·
52 minutes ago
S&P 500 Unusual Volume Movers for Oct. 30, 2026
TradingView
·
1 hour ago
MARKETS UPDATE: NASDAQ -809/-3.09%; S&P -149/-1.9%; DJIA -522/-1%; VIX 21.15; US 10-YR YIELD 4.941%, +0.002; 2-YR 4.594%, -.008; 30-YR 5. 314, +0.012
Seeking Alpha
·
3 hours ago
Bad Day... Or Was It?
The Motley Fool
·
2 hours ago
Micron Became One of the 10 Biggest Holdings in S&P 500 Index Funds. What Does That Mean for the Stock?
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA